Patient-Focused Drug Development
Tuberous Sclerosis Complex Patient-Focused Drug Development Meeting
The TS Alliance sponsored a patient-focused drug development meeting (PFDD) with the FDA on June 21, 2017, at the Hyatt Regency on Capitol Hill in Washington, DC, from 8:30 a.m. to 4:30 p.m. The purpose of this meeting was for individuals affected by TSC and caregivers of dependent adults or children to communicate their perspectives on living with TSC to the FDA. This meeting was free and open to the public, and it was webcast live online.
The TSC PFDD meeting was divided into two parts. The morning focused on input from parents of children with TSC who have experienced, or are at risk for developing, epilepsy. The afternoon focused on adults with TSC and/or LAM who have experienced, or are at risk for developing, angiomyolipomas or LAM. The TSC PFDD meeting was designed to communicate to FDA the impacts of TSC on individuals’ daily lives, what types of treatment benefits make the most impact on peoples’ lives, and individuals’ and caregivers’ perspectives on how well available therapies are working.
If you were unable to attend the PFDD meeting in person or online, you can view recordings of the meeting below:
Morning Session: Infants with TSC, Part 1
Morning Session, Infants with TSC, Part 2
Afternoon Session: Adults with TSC and/or LAM, Part 1
Afternoon Session: Adults with TSC and/or LAM, Part 2